ClinicalTrials.gg
WithdrawnNCT03481842ELTAUpdated Oct 29, 2021

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

A Phase 1/2 interventional study of Linifanib and BIBW2992 in Endometriosis, Endometriosis Ovary and Endometriosis Externa, sponsored by BioGene Pharmaceutical Ltd.. Withdrawn at 1 site in Switzerland. Open to female participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by BioGene Pharmaceutical Ltd. · Phase 1/2, Interventional, and Prevention

How we know

Why this study was withdrawn
Change in study design and sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
19 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Endometriosis with a site in Switzerland — 8 open to participants now, 8 under way, 1 of them phase 3. Endometriosis · Switzerland.

Enrollment
12th of 12
0 · median 91
Started
2021
with 1 other
Phase 1/2
2 of 21
1 open now
Registered
4th of 21
by date
Lead sponsor
1 of 21
BioGene Pharmaceutical Ltd.

Among the 21 studies in Endometriosis with a site in Switzerland, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1/2, and was the 4th registered.

Endometriosis

922 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

8 of the 21 studies in Endometriosis with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 179 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 125 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 19 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Endometriosis with a site in Switzerland, or all of them as a file.
02

Study summary

Background:

Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.

Types of endometriosis:

Endometriosis is divided into genital and extragenital. Genital endometriosis is internal and external. When the inner is affected by the uterus, with the external - the ovaries, tubes, vagina and external genital organs are affected. Extragenital endometriosis can affect various organs of the abdominal cavity.

Drug treatment does not show high effectiveness. Surgery / laparoscopic is currently considered the gold standard treatment for this problem, including infertility treatment.

The purpose of our studies is to achieve substantial results with respect to tolerability, safety and clinical efficacy of vaginal suppository ELTA for treatment of the endometriosis.

Methods:

Phase I clinical trial to be conducted at Cancer Center to hold under the aegis UniversitätsSpital Zürich from May 2018 to September 2018.

Ninety-four patients with the form of genital endometriosis will take part in the studies. The study was approved by the Ethics Committee at the Cancer Institute no C99884.01FH339

Read the detailed description

The composition of the endometrium includes epithelial cell layers lining the uterine cavity, and deeper stroma, including the secretory glands. Each layer is characterized by the presence of a large number of blood vessels, through which a sufficient amount of blood is delivered. A large number of these vessels and arteries go to the surface layers due to myometrium and form a capillary network in the stroma.

In the vaginal suppositories, the investigators applied minimally therapeutic doses of inhibitors of neoangiogenesis, as well as other components that caused the pathological growth of the endometrium.

Anti-angiogenic therapy - inhibition of proliferative processes in the vascular wall of capillaries and small vessels in the endometrium, is the determining factor of the therapeutic effect of endometriosis when treated with vaginal suppositories.

The composition of the suppository:

  • Axitinib, Afatinib, Linifanib (ABT-869) in a minimally sufficient therapeutic doses
  • Auxiliary substances that ensure a uniform release of active components from suppositories, taking into account the dependence of this process on the chemical nature of the basis, surfactant, dissolution medium.

(the composition and amount of excipients are maximally optimal for bioavailability of drugs from suppositories, taking into account the pharmacokinetics, pharmacodynamics and synergy of active drugs) This therapy has a slight teratogenic effect, which should be taken into account when planning pregnancy.

03

Conditions studied

  • Endometriosis
  • Endometriosis Ovary
  • Endometriosis Externa
  • Endometriosis, Rectum

Browse trials for

Keywords

  • Endometriosis
  • VEGF(R)
04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • verification of endometriosis
  • signed agreement of
  • agreement with information on the nature, relevance and scope of the investigation, as well as the expected results and undesirable consequences of IMD

Exclusion criteria

Exclusion Criteria:

  • use of not permitted or not willing to use contraception
  • pregnancy or lactation
  • planned pregnancy in the next 36 months with the consent to participate in that clinical trial
  • use of any other intravaginal medicinal product or medical device
  • known to one or more of the active and / or inactive ingredients
  • acute or chronic renal failure
  • acute or chronic heart failure
  • the patient's reluctance to follow the trial protocol
  • chronic alcoholism
  • drug addiction
  • use of antidepressants (during participation in trial)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vaginal Suppositories

    Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA The composition of the suppository: * Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose * Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose * Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose

    Biological: Linifanib · Drug: BIBW2992 · Drug: Axitinib

Interventions

  • BiologicalLinifanib

    in a minimally sufficient therapeutic dose

    Also known as: ABT869

  • DrugAfatinibStudies of AfatinibAfatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    in a minimally sufficient therapeutic dose

    Also known as: Afatinib, Giotrif

  • in a minimally sufficient therapeutic dose

    Also known as: AG013736;, Inlyta

06

What researchers measure

Primary outcomes

  1. Local tolerability of the vaginal suppository ELTA defined as a cumulative sum of clinical signs for each patient

    Local tolerability of the vaginal suppositories ELTA will be defined as a cumulative sum score of the solicited local /vaginal (consisting of subjectively experienced symptoms rated by the patient: burning, itching, bleeding, pain, dryness and objectively documented findings rated by the physician: redness, petechial bleeding, dryness, swelling) for each patient after every weeks of application (scored from 0 \[none/normal\] to 5 \[severe\]) Weekly visit of patients every seventh day from the beginning of treatment. SCALE EVALUATION EVENTS * burning - 2 points, * dryness - 1 point, * painful symptom- 3 points, * itching - 1 point, * bleeding - 5 points, If there is bleeding or the development of edema - the study for the patient will be stopped.

    Time frame: 6 weeks

Secondary outcomes

  1. Subjective symptoms (local tolerability)

    Each of the subjective symptoms (scored from 0 \[none/normal\] to 5 \[severe\]) from the first visit (after the first application)/ A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)

    Time frame: 7 weeks

Other outcomes

  1. Objective findings

    Each of the objective symptoms (scored from 0 \[none/normal\] to 3 \[severe\]) from the first visit (after the first application). * dryness, itching, hyperemia of the perineum - 1 point, * pain syndrome with itching / dryness or without - 2 points, * bleeding with pain syndrome (or other symptoms / without them - 3 points, A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)

    Time frame: 7 weeks

  2. Global judgement of tolerability

    Global judgement of tolerability by investigator and patients. The scores of the Clinical Global Impression (CGI) Scale.

    Time frame: 4 weeks

  3. Safety evaluation of therapy

    Safety evaluation of therapy. Drugs safety will be evaluated by assessment of adverse events ( ADRs).

    Time frame: 15 weeks

  4. Serious Adverse Event.

    Occurrence of AE / SAE / ADE / SADE. Characteristics of occured AE / SAE / ADE / SADE

    Time frame: up to 15 weeks

  5. Change in pH-value from vaginal smear

    pH-value from vaginal smear at every visit for each patient after the 3rd and 6th week of application of suppositories.

    Time frame: up to 6 weeks

  6. Change in Vaginal flora

    Vaginal flora (Lactobacillus spp., Atopobium vaginae and Gardnerella vaginalis) on the first day of intake (before using the first suppository) and on the day of termination of therapy

    Time frame: up to 15 weeks

  7. Other signs of assessing the hip therapy

    Mandatory Clinical blood test for each patient after the 3rd and 6th week of application of suppositories. A control blood test on the first day of the 15th week after the start of the first suppository

    Time frame: up to 15 weeks

07

Study locations

1 site
  • BioGene Pharmaceutical Ltd.
    Basel, Вâlе 4057, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Oct 2021, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 29, 2018
StartEst.
Oct 10, 2021
Primary completionEst.
Oct 10, 2021
CompletionEst.
Oct 10, 2021
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03481842
Lead sponsor
BioGene Pharmaceutical Ltd.
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Oct 10, 2021 (estimated)
Primary completion
Oct 10, 2021 (estimated)
Completion
Oct 10, 2021 (estimated)
Last update
Oct 29, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afatinib

Start the discussion